Claim Missing Document
Check
Articles

Found 2 Documents
Search

Hypoxia Precondition Enhance the Therapeutic Effects of Mesenchymal Stem Cells via regulating TGF-β1 and IL-10 serial expression in Skin Excision Rat Models Kustyah, Azizah Retno; Fatimah, Nandiah; Rizkiyani, Elytia Mutia; Ramadhanti, Olifiarsy Wiet; Istiqomah, Dyah Ayu Fitri; Hidayah, Nurul; Bhirau Wilaksono
International Journal of Cell and Biomedical Science Vol 1 No 1 (2022)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v1i1.9

Abstract

Background: The skin excisional wound healing process involves an intricate-regulated series of cellular responses to reverse the formation of skin tissue integrity. This process requires paracrine communication involving anti-inflammatory cytokines and growth factors, especially interleukin 10 (IL-10) and TGF-β. On the other hand, hypoxic preconditioned mesenchymal stem cells (Hypoxia-MSCs) have been acknowledged to enrich IL-10 and TGF- β secretion contributing to accelerated wound healing compared to normal preconditioned mesenchymal stem cells (Normoxia-MSCs). Objective: This study aimed to compare Hypoxia-MSCs and Normoxia-MSCs in integrating the serial expression of IL-10 and TGF-β associated with improved collagen density in animal models of excision wounds. Methods: Thirty-six male Wistar rats with excision wounds were made as animal models using the 6 mm biopsy method. The rats were randomly divided into four groups consisting of four treatment groups: N-MSCs 1x106, H-MSCs 1x106, Control (PBS treatment), and Sham (untreated or healthy mice). The treatments were administered 2 times intraperitoneally on day 0. Skin tissue was collected on days 12, 18, and 24 post-injections. IL-10 dan TGF-β expressions were examined by qPCR. Results: This study showed that there was a significant increase in IL-10 and TGF-β after Hypoxia-MSCs and Normoxia-MSCs treatment compared to the Control group. Conclusion: Hypoxia-MSCs can improve the serial expression of IL-10 which leads to wound repair of the mouse model of excision wound. These results suggest that a hypoxic environment can enhance the therapeutic effect of MSCs.
The Effect of Hypoxic Mesenchymal Stem Cells on the expression of Transforming Growth Factors in Wistar Rats Excision Wound Model Istiqomah, Dyah Ayu Fitri; Djannah, Durrotul; Mulyani, Sri Priyantini
International Journal of Cell and Biomedical Science Vol 1 No 2 (2022)
Publisher : Stem Cell and Cancer Research (SCCR)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59278/cbs.v1i2.16

Abstract

Background: Hypoxic Mesenchymal stem cell (MSC) therapy may accelerate the wound healing process through a paracrine mechanism by increasing the expression of transforming growth factor-β (TGF-β). Objective: This study aims to investigate the effect of hypoxic MSC on TGF-β gene expression in excision wound models. Methods: This is an experimental study with a post-test-only control group design. Sixty male Wistar rats were divided into 4 groups consisting of 5 each to represent group I (sham/normal control), group II (excision wound model), group III (excision wound model and normoxic MSC injection), group IV (excision wound model and hypoxic MSC injection) for observation of TGF-β gene expression on days 3, 6 and 9. Both MSC (3x106 cells) were injected subcutaneously after wound excision at five locations 0,5 cm from the wound edge. TGF-β gene expression was examined by qRT-PCR. Results: The highest average TGF-β gene expression on the three observation days were shown by group II. TGF-β gene expression in groups III and IV was lower than in group II, while groups III and IV were relatively similar. In the normal wound healing process, TGF-β is highly expressed, and both MSC injection reduces TGF-β gene expression. Conclusion: Hypoxic MSC injection accelerated the proliferative phase of the excisional wound healing process, but the acceleration effect was equivalent to that shown by Normoxic MSC.